Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
02.07. | Elevation Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
ELEVATION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
10.06. | Elevation Oncology stock holds Market Perform post-acquisition | 2 | Investing.com | ||
10.06. | Elevation Oncology-Aktie bleibt nach Übernahme auf "Market Perform" | 16 | Investing.com Deutsch | ||
09.06. | TD Cowen cuts Elevation Oncology stock rating to Hold | 3 | Investing.com | ||
09.06. | TD Cowen stuft Elevation Oncology auf "Halten" herab | 2 | Investing.com Deutsch | ||
09.06. | Concentra to acquire Elevation Oncology in bid to eliminate another biotech 'zombie' | 1 | BioPharma Dive | ||
09.06. | Embattled Elevation Oncology becomes latest biotech to accept Concentra buyout offer | 1 | FierceBiotech | ||
09.06. | Elevation Oncology-Aktie steigt nach Fusionsvereinbarung mit Concentra | 1 | Investing.com Deutsch | ||
09.06. | Elevation Oncology stock soars on Concentra merger agreement | 3 | Investing.com | ||
09.06. | Elevation Oncology To Be Bought By Concentra Biosciences For $0.36/shr In Cash Plus CVR; Stock Gains | - | RTTNews | ||
09.06. | Elevation Oncology stimmt Übernahme durch Concentra Biosciences zu | 14 | Investing.com Deutsch | ||
09.06. | Elevation Oncology agrees to Concentra Biosciences buyout | 2 | Investing.com | ||
09.06. | Elevation Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
15.05. | Elevation Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
15.05. | Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | 74 | PR Newswire | -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting --
-- Expects to file IND application for EO-1022 in 2026... ► Artikel lesen | |
15.05. | Elevation Oncology, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
05.05. | Elevation Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
25.04. | Elevation Oncology reveals promising ADC data for solid tumors | 1 | Investing.com | ||
25.04. | Elevation Oncology präsentiert vielversprechende ADC-Daten für solide Tumore | 1 | Investing.com Deutsch | ||
01.04. | Elevation Oncology, Inc. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 27,065 | +0,84 % | Moderna: Höchste Zeit zum Einstieg? | Der lange Abwärtstrend seit dem Corona-Hype könnte für die Moderna-Aktie ein Ende gefunden haben: Kann der Titel bald wieder an alte Glanzzeiten anknüpfen? Das erste Halbjahr verlief für Moderna und... ► Artikel lesen | |
CRISPR THERAPEUTICS | 56,00 | 0,00 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
PALATIN TECHNOLOGIES | 0,145 | +20,90 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
BIOXXMED | 0,310 | -24,39 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,881 | +2,47 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 1,010 | -2,88 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,390 | -2,01 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
TEMPUS AI | 52,00 | +4,42 % | Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer | ||
VAXART | 0,350 | +0,29 % | OTC Markets Group Welcomes Vaxart, Inc. to OTCQX | NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX:... ► Artikel lesen | |
BURCON NUTRASCIENCE | 1,690 | -3,98 % | Burcon NutraScience Corporation: Burcon to Showcase Chipotle Black Bean Protein Hummus at 2025 IFT FIRST Annual Event & Expo | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 5,250 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc. - S-8, Securities to be offered to employees in employee benefit plans |